Amarin Corp Plcuk (AMRN) Short-term Investments (2020 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Short-term Investments of $176.8 million for Q1 2026, up 8.96% YoY from $162.3 million in Q1 2025, and up 5.28% sequentially from $167.9 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Short-term Investments (2020 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Short-term Investments across 7 years of filings, most recently posting $176.8 million for Q1 2026.
- In Q1 2026, Short-term Investments rose 8.96% year-over-year to $176.8 million; the TTM figure through Mar 2026 stood at $176.8 million (up 8.96% YoY), while the FY2025 annual figure was $167.9 million, down 3.03% from the prior year.
- Short-term Investments climbed to $176.8 million in Q1 2026, from $167.9 million in the prior quarter.
- Over the last five years, Short-term Investments for AMRN reached as high as $176.8 million in Q1 2026 and fell as low as $49.8 million in Q3 2023.
- The 5-year median for Short-term Investments is $121.4 million (2023), against an average of $122.1 million.
- Annual changes were most pronounced in 2022 — Short-term Investments sank 75.34% — and 2024, when it soared 198.48%.
- A 5-year view of Short-term Investments shows it stood at $91.7 million in 2022, then surged by 32.4% to $121.4 million in 2023, then surged by 42.65% to $173.2 million in 2024, then decreased by 3.03% to $167.9 million in 2025, then climbed by 5.28% to $176.8 million in 2026.
- According to Business Quant data, Short-term Investments over the past three periods registered $176.8 million, $167.9 million, and $163.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 176.80 Mn |
| Dec 31, 2025 | 167.93 Mn |
| Sep 30, 2025 | 163.80 Mn |
| Jun 30, 2025 | 150.80 Mn |
| Mar 31, 2025 | 162.26 Mn |
| Dec 31, 2024 | 173.18 Mn |
| Sep 30, 2024 | 148.79 Mn |
| Jun 30, 2024 | 90.70 Mn |
| Mar 31, 2024 | 94.24 Mn |
| Dec 31, 2023 | 121.41 Mn |
| Sep 30, 2023 | 49.85 Mn |
| Jun 30, 2023 | 79.90 Mn |
| Mar 31, 2023 | 112.96 Mn |
| Dec 31, 2022 | 91.70 Mn |
| Sep 30, 2022 | 63.20 Mn |
| Jun 30, 2022 | 85.23 Mn |
| Mar 31, 2022 | 143.41 Mn |
| Dec 31, 2021 | 234.67 Mn |
| Sep 30, 2021 | 256.30 Mn |
| Jun 30, 2021 | 181.91 Mn |